Bolt Biotherapeutics faces a precarious financial outlook characterized by a rapid depletion of its asset base, which has fallen from $159.8 million in 2023Q4 to $48.0 million in 2026Q1. The company's reliance on lumpy, non-recurring milestone payments has fai...
Price trend, volume and key moving averages
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 11, 2026 | -$4.57-34.8% vs -$3.39 | $5,000-99.0% vs $500,000 |
Q2 2026 May 12, 2026 | -$4.31-51.2% vs -$2.85 | $26,000-98.3% vs $2M |
Q2 2026 Mar 12, 2026 | -$3.84+10.7% vs -$4.30 | $3M+275.0% vs $666,667 |
Q4 2025 Nov 12, 2025 | -$3.72+26.6% vs -$5.07 | $2M+164.3% vs $820,800 |
Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $4.57 per share versus the Zacks Consensus Estimate of a loss of $2.97. This compares to a loss of $4.46 per share a year ago.
First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected to be released with Bolt's 3Q 2026 results Cash balance of $18.1 million as of June 30, 2026 anticipated to fund operations into 1Q 2027 REDWOOD CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2026, and provided a business update.
Benchmark BOLT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Bolt Biotherapeutics, Inc. (BOLT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.63 | $6.98M | -0.20 | 0.07% | -433.74% | -79.75% | — | |
| $26.87 | $3.38B | -8.17 | -4.26% | -386.32% | -87.98% | — | |
| $8.70 | $362.29M | -2558.82 | 10.37% | 69.76% | — | — | |
| $37.29 | $7.7B | -13.46 | — | -7585.86% | -69.59% | — | |
| $58.11 | $8.9B | 20.98 | 87.32% | 55.22% | 72.3% | — | |
| $18.19 | $1.61B | -5.53 | 627.84% | -87.6% | -372.94% | — |
Bolt Biotherapeutics, Inc. (BOLT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Bolt Biotherapeutics, Inc. (BOLT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 11, 2026·SEC
Jun 11, 2026·SEC
May 12, 2026·SEC
Get notified when BOLT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Bolt Biotherapeutics, Inc. (BOLT) stock FAQ — growth, dividends, profitability & financials explained
Bolt Biotherapeutics, Inc. (BOLT) reported $4.7M in revenue for fiscal year 2025.
Bolt Biotherapeutics, Inc. (BOLT) grew revenue by 0.1% over the past year. Growth has been modest.
Bolt Biotherapeutics, Inc. (BOLT) reported a net loss of $28.7M for fiscal year 2025.
Bolt Biotherapeutics, Inc. (BOLT) has a return on equity (ROE) of -79.7%. Negative ROE indicates the company is unprofitable.
Bolt Biotherapeutics, Inc. (BOLT) had negative free cash flow of $31.5M in fiscal year 2025, likely due to heavy capital investments.
